MODIFIED ANTIGEN-BINDING FAB FRAGMENTS AND ANTIGEN-BINDING MOLECULES COMPRISING THE SAME

NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF

Fc mutants with improved functional activity

Bispecific Polypeptides to GITR and CTLA-4

Anti-GITR antibodies and methods of use thereof

ANTI-RANKL ANTIBODIES AND METHODS OF USE

Methods of treatment using a leptin receptor agonist antibody

Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment

Compositions and methods comprising anti-NRP2 antibodies

PD-1 antibody, antigen-binding fragment thereof, and medical application thereof

Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseases

Anti-TREM2 antibodies and related methods

Anti-human Igβ antibody

Methods and agents for the diagnosis and treatment of hepatocellular carcinoma

INTESTINAL ANTIGENS FOR PHARMACODELIVERY APPLICATIONS

HIGHLY GALACTOSYLATED ANTI-TNF-ALPHA ANTIBODIES AND USES THEREOF

HIGHLY GALACTOSYLATED ANTI-TNF-ALPHA ANTIBODIES AND USES THEREOF

Immunoglobulin single variable domains directed against macrophage migration inhibitory factor

Anti-BAFF antibodies

Compositions

Immune complex

Anti-TMPRSS2 antibodies and antigen-binding fragments

Anti-PSMA antibodies, uses thereof and conjugates thereof

Conjugates of IL13Rα2 binding agents and use thereof in cancer treatment

ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF

Anti-CD25 antibody agents

Anti-canine platelet derived growth factor receptor alpha antibody

Therapeutic CD47 antibodies

Anti-TREM-1 antibodies and uses thereof

COMPOSITION CONTAINING ANTI-ROBO4 ANTIBODY AND OTHER AGENTS

Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof

PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE

Anti-equol antibody composition and use therefor

Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors

Anti-ICOS agonist antibodies and uses thereof

Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof

MYCOBACTERIUM TUBERCULOSIS PROTEINS IN DIAGNOSTIC ASSAYS AND DEVICES FOR TUBERCULOSIS DETECTION AND DIAGNOSIS

Internalizing moieties

Binding molecules specific for CD73 and uses thereof

ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF

Methods for producing fabs and IgG bispecific antibodies

Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity

NOVEL BINDING PROTEINS COMPRISING A UBIQUITIN MUTEIN AND ANTIBODIES OR ANTIBODY FRAGMENTS

KLRG1 antagonist signaling therapy

GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF

Anti-PD-1 antibodies

Anti-CD47 antibodies

Amyloid beta oligomer specific binding molecule

Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies

Composition and method for the diagnosis and treatment of iron-related disorders

Hybridoma cell line of secreting clarithromycin monoclonal antibodies and preparation method thereof

Human anti-SOD1 antibodies

Heterodimeric immunoglobulin constructs and preparation methods thereof

Antibodies that bind CD39 and uses thereof

4-1BB binding proteins and uses thereof

Anti-OX40 antibodies

Anti-RANKL antibodies and uses thereof

Anti-CD25 antibody agents

BISPECIFIC ANTIBODY BINDING TO HUMAN CD19 AND CD3

Humanized or chimeric CD3 antibodies

Anti-LAG3 antibodies and uses thereof

T cell receptors and immune therapy using the same

Anti-KRAS binding proteins

ERFE SPECIFIC ANTIBODIES COMPOSITIONS AND METHODS OF USE

Interleukin-31 monoclonal antibodies for veterinary use

Tau-binding antibodies

Antibodies specific for hyperphosphorylated tau and methods of use thereof

Antibodies specific for hyperphosphorylated tau and methods of use thereof

T cell receptor-like antibodies specific for Foxp3-derived peptides

Anti-TIE2 antibodies and uses thereof

Thrombin-Binding Antibody Molecules And Uses Thereof

TAG-72-binding chimeric antigen receptors

Antigen-binding polypeptides directed against CD38

POLYPEPTIDE VARIANTS AND USES THEREOF

Anti-NGF antibodies and methods thereof

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

Anti-PD1 and anti-CTLA4 antibodies

HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

ANTIGEN BINDING PROTEINS

Anti-Tim-3 antibodies for combination with anti-PD-1 antibodies

Anti-Tim-3 antibodies and use thereof

Anti-TIM-3 antibodies and compositions

Composition and methods of treating B cell disorders

Antibodies to alpha-synuclein and uses thereof

Human Zika virus antibodies and methods of use therefor

Immunogenetic restriction on elicitation of antibodies

Anti-SIRP-alpha antibodies and methods of use thereof

Antibodies binding AXL

Antibodies to CD70

Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Anti-PD-1 antibodies

Antibodies specific to FCRN

Humanized anti-BASIGIN antibodies and the use thereof

Methods of determining whether anti-PACAP antibodies inhibit PACAP-associated photophobia or light aversion

IL-6 antibodies and fusion constructs and conjugates thereof

ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER

IL-17 ANTAGONISTIC ANTIBODIES

RGMa binding protein and use thereof

Anti-ApoE antibodies

Anti-human MUC1 antibody fab fragment

Cytotoxic benzodiazepine derivatives

Preparation of bioconjugates and antibodies for the immunodetection of anatoxin-a

Anti-TrkA antibody

Antibodies directed to HER-3 and uses thereof

Cytotoxic benzodiazepine derivatives

CD20 antibodies

Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma

Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity

Cysteine engineered fibronectin type III domain binding molecules

Bispecific and monospecific antibodies using novel anti-PD-1 sequences

Antibody constructs for DLL3 and CD3

CD3 binding antibodies

Humanized M-CSF specific monoclonal antibodies, kits, and uses thereof

Anti-tau nanobodies

Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies

Recombinant antibody and uses thereof

Fibronectin based scaffold proteins having improved stability

Relaxin immunoglobulin fusion proteins and methods of use

Immunoglobulins and uses thereof

PROTEIN CAPABLE OF BINDING SPECIFICALLY TO IMMUNOGLOBULIN, AND IMMUNOGLOBULIN-BINDING AFFINITY LIGAND

Glucocorticoid receptor agonist and immunoconjugates thereof

Antibodies specific for LOX1 and use in treatment of cardiovascular disorders

Genetically modified non-human animals and methods for producing heavy chain-only antibodies

Nucleic acids encoding high affinity antibodies to human IL-6 receptor

Dual receptor antagonistic antigen-binding proteins and uses thereof

Binding molecules binding PD-L1 and LAG-3

Anti-PD-1 antibodies and methods of use thereof

Antibodies directed against programmed death-1 (PD-1)

Anti-ICOS and anti-PD-1 antibody combination therapy

Anti-CD73 antibodies and uses thereof

Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

CD33 BINDING AGENTS

Antibody specifically binding to IL-17A, encoding nucleic acid, and method of using the antibody

Antibody specifically binding to an isolated peptide derived from vimentin or a fragment binding to the peptide

Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use

T cell receptors and immune therapy using the same against prame positive cancers

Method of treating inflammatory bowel disease

Use of myostatin inhibitors and combination therapies

Fusion proteins comprising enzyme replacement therapy enzymes

Chemically-locked bispecific antibodies

Bi-specific antigen-binding polypeptides

Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers

Antibodies binding to HLA-A2/WT1

Nucleic acids encoding an anti-CD40 antibody

Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Anti-human BDCA-2 antibody

Anti-CLL-1 antibodies and immunoconjugates

Methods of treating cardiovascular disease with an anti-ASGR antibody or binding fragments thereof

Antibodies to MICA and MICB proteins

Antibody to programmed cell death 1 (PD-1) and use thereof

Mixtures of antibodies

Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs

TREATMENT WITH ANTI-KIR3DL2 AGENTS

Anti-FcRn antibodies

EXTRACELLULAR TARGETED DRUG CONJUGATES

Method for treating lupus by administering an anti-IL-12 antibody

Methods of treating cancer with human monoclonal antibodies against interleukin 8 (IL-8)

Heavy chain only antibodies to ANG-2

Neutralizing anti-influenza A virus antibodies and uses thereof

Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS

Anti-PD-L1-anti-TIM-3 bispecific antibodies

Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof

Antibodies that bind Notum Pectinacetylesterase

Anti-MERTK agonistic antibodies and uses thereof

Chimeric antigen receptors targeting B-cell maturation antigen

Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells

Anti-B7-H4 antibodies and immunoconjugates

Anti-CTLA4 antibodies and methods of making and using the same

BISPECIFIC ANTIBODY-LIKE BINDING PROTEINS SPECIFICALLY BINDING TO CD3 AND CD123

Antibodies with low immunogenicity and uses thereof

MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF

Anti-ApoC3 antibodies and methods of use thereof

Compositions And Methods For Treating Angiogenesis-Related Disorders

ANTIGEN-COUPLED HYBRIDIZATION REAGENTS

Low-viscosity antigen binding proteins and methods of making them

Anti-PCSK9 antibodies

Anti-PCSK9 antibody and use thereof

HER2/neu-specific antibodies and methods of using same

Humanized antibody against O-acetylated GD2 ganglioside (OAcGD2)

IFN-γ-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof

Site-specific antibody-drug conjugation through glycoengineering

Antibodies specific for CD70 and their uses

Chimeric antigen receptors targeting CD70

ANTI-HUMAN CD69 ANTIBODY, AND USE THEREOF FOR MEDICAL PURPOSES

ANTI HLA-G SPECIFIC ANTIBODIES

Single-domain antibodies and variants thereof against CTLA-4

Anti-PD-1/LAG3 bispecific antibodies

Fabs-in-tandem immunoglobulin and uses thereof

ANTI-FOLATE RECEPTOR ANTIBODIES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODIES AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODIES

IL-6 binding molecules

Methods of detecting human IL-21

Human Anti-Tau Antibodies

Neutralizing anti-influenza B antibodies and uses thereof

Anti-PACAP antibodies and uses thereof

KIDNEY DISEASE TARGETS AND USES THEREOF

FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY AND METHODS OF TREATMENT

Vaccine composition comprising cyclic peptides, antibodies to the cyclic peptides or an anticancer composition comprising the same

Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)

Diagnostic assays and kits for detection of folate receptor 1

Influenza mucosal vaccine composition and preparation and application thereof

Antibodies with reduced binding to process impurities

Antibodies against factor XI and uses thereof

CD73 blocking agents

Methods for the treatment of thyroid eye disease

Anti-PD-L1 antibodies and variants

Anti-CTLA4 antibodies

Anti-LAG-3 antibodies and uses thereof

Anti-IGF antibodies

Tenascin Epitope and Antibodies Thereto

Fusion proteins for opthalmology with increased eye retention

Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein

TRANSGENIC NON-HUMAN ANIMALS PRODUCING MODIFIED HEAVY CHAIN-ONLY ANTIBODIES

Antigen binding proteins that bind WISP1

Human antibody specifically binding to acne bacteria using phage display technique, and use thereof

Cellular vamp cleavage assay

Bispecific antigen binding construct

Drug containing carrier into cell for forming immune complex

RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS

CD37-binding molecules and immunoconjugates thereof

Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy

Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1

Anti-PD-L1 antibodies and methods of use

Anti-PD-1 antibodies

Compositions for achieving therapeutically effective doses of anti-CD47 agents

FcγRIIB-specific antibodies and methods of use thereof

Compositions and methods for measuring NMU and for treatment using anti-NMU agents

Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies

NOVEL ANTIBODY FORMAT

PAC1 antibodies and uses thereof

Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use

Immunoglobulin constant region Fc receptor binding agents

Antibody-polymer-drug conjugates

Methods for producing Fabs and bi-specific antibodies

Method of inhibiting the enzymatic activity of vascular endothelial lipase with a monoclonal antibody

BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR

Amino acid sequences that modulate the interaction between cells of the immune system

Human CD3 binding antibody

USE OF PILRA BINDING AGENTS FOR TREATMENT OF A DISEASE

Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells

Anti-complement factor C1q antibodies and uses thereof

Human immunodeficiency virus neutralizing antibodies

Method for purifying antibody or antibody fragment containing κ-chain variable region

ANTIBODY CONSTANT REGION VARIANT

Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer

Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies

Quantitative ligandomics for systematic identification of therapeutic ligands

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARTYL-TRNA SYNTHETASES

Heterodimeric antibodies that bind CD3 and tumor antigens

Low affinity blood brain barrier receptor antibodies and uses thereof

Cys80 conjugated immunoglobulins

ANTI- EGFR CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF

Humanized Anti-CD134 (OX40) Antibodies And Uses Thereof

Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor

Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

EGFR binding molecules

Antibodies binding CTLA-4 and uses thereof

Antibodies for Siglec-15 and methods of use thereof

Methods for treating autoimmune diseases incorporating an anti-LAG3 antibody

Antibodies against Frizzled receptor

Antibodies for IL-17C

Synthetic antibodies against VEGF and their uses

Anti-VEGF-A antibodies and uses thereof

ANTIBODY VARIANTS

AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF

Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR

Compositions relating to a mutant clostridium difficile toxin and methods thereof

Anti-IL-23 antibodies

Cysteine-optimized stradomers

Antibody to Renalase

Tissue plasminogen activator antibodies and methods of use

MONOCLONAL ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI)

Anti-factor IX Padua antibodies

Antigen binding protein against HER3

ANTIBODIES SELECTIVE FOR CELLS PRESENTING ERBB2 AT HIGH DENSITY

ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)

Anti-5T4 antibodies and antibody-drug conjugates

ANTI-SAS1B ANTIBODIES, ASSOCIATED METHODS OF USE, AND COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CANCER

Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist

Antibodies specific for epidermal growth factor receptor variant III and their uses

Anti-TEM1 antibodies and uses thereof

TREATMENT OF PD-L1-NEGATIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY

Antibodies to LILRB2

Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients

Anti-Siglec-7 antibodies for the treatment of cancer

Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)

IL-6 antibodies

Anti-TNF-alpha-antibodies and functional fragments thereof

Macrophage stimulating protein receptor (or RON—recepteur d'Origine Nantais) antibodies and uses thereof

Anti-VEGF-A and anti-ANG2 antibodies and uses thereof

Single domain binding molecule

Variant antibodies that bind AIP2

Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof

C-TERMINALLY FUSED TNF FAMILY LIGAND TRIMER-CONTAINING ANTIGEN BINDING MOLECULES

Use of FCRN antagonists for treatment of generalized myasthenia gravis